Dongcheng Pharmaceuticals: Controlled subsidiary receives Notice of Approval for Clinical Trials of Drugs

Dongcheng Pharmaceutical announced that its holding subsidiary, Lanna Cheng, has received the approval notice for the clinical trial of 225Ac-LNC1011 injection issued by the National Medical Products Administration. The clinical trial will be conducted in the near future. 225Ac-LNC1011 injection is a targeted alpha-particle radiotherapeutic drug specific to prostate-specific membrane antigen, intended for the treatment of late-stage prostate cancer patients with PSMA-positive expression. Currently, there is no similar product on the market domestically or internationally, and there is no relevant sales data available.